Enzo Biochem to Present at Canaccord Genuity 2012 Medical Technology &
NEW YORK -- November 29, 2012
Enzo Biochem, Inc. (NYSE:ENZ), a vertically integrated biosciences and
clinical laboratory company, announced today that Barry Weiner, President, and
David Goldberg, Vice President, Corporate Development, will be presenting at
the Canaccord Genuity 2012 Medical Technology & Diagnostics Forum on Tuesday,
December 4, 2012 at 8:30 AM at Le Parker Meridien, in New York, N.Y.
About Enzo Biochem
Enzo Biochem, Inc., is a growth-oriented integrated life sciences and
biotechnology company focused on harnessing biological process to develop
research tools, diagnostics and therapeutics, and serves as a provider of test
services, including exotic tests, to the medical community. Since our founding
in 1976, our strategic focus has been on the development of enabling
technologies in the life sciences field. Enzo Life Sciences develops, produces
and markets proprietary labeling and detection products for gene sequencing,
genetic analysis and immunological research, among others. Its catalog of over
30,000 products serves the molecular biology, drug discovery and pathology
research markets worldwide. Enzo Clinical Labs provides laboratory services
for a growing roster of physicians in the New York Metropolitan area,
Pennsylvania and New Jersey. Its tests include, in addition to routine tests,
capabilities for detecting molecular infection disease, molecular oncology,
autoimmune disorders and genetics. Enzo Clinical Labs also provides clinical
diagnostic services that allow Enzo to capitalize on its extensive advanced
molecular and cytogenetic capabilities and the broader trends in predictive
and personalized diagnostics. Enzo Therapeutics is a biopharmaceutical venture
that has developed multiple novel approaches in the areas of gastrointestinal,
infectious, ophthalmic and metabolic diseases. It has focused its efforts on
developing treatment regimens for diseases and conditions for which current
treatment options are ineffective, costly, and/or cause unwanted side effects.
In the course of the company’s research and development activities, Enzo has
also developed a substantial portfolio of intellectual property asset with
patent coverage across a number of key technologies.
Except for historical information, the matters discussed in this news release
may be considered "forward-looking" statements within the meaning of Section
27A of the Securities Act of 1933, as amended and Section 21E of the
Securities Exchange Act of 1934, as amended. Such statements include
declarations regarding the intent, belief or current expectations of the
Company and its management, including those related to cash flow, gross
margins, revenues, and expenses are dependent on a number of factors outside
of the control of the company including, inter alia, the markets for the
Company’s products and services, costs of goods and services, other expenses,
government regulations, litigations, and general business conditions. See Risk
Factors in the Company’s Form 10-K for the fiscal year ended July 31, 2010.
Investors are cautioned that any such forward-looking statements are not
guarantees of future performance and involve a number of risks and
uncertainties that could materially affect actual results. The Company
disclaims any obligations to update any forward-looking statement as a result
of developments occurring after the date of this press release.
Enzo Biochem, Inc.
Steven Anreder, 212-532-3232
Michael Wachs, 212-732-4300
Press spacebar to pause and continue. Press esc to stop.